MedTrace Logo

JSKN022 in Subjects With Advanced Malignant Solid Tumors

NCT07292402 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-12-23

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

JSKN022

JSKN022 administered intravenously at selected dose levels according to protocol

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-23
Primary Completion
2027-08-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07292402 on ClinicalTrials.gov